Pfizer Ignite News Today

2023 Sets Stage for Future Growth Potential: Completed Seagen Acquisition, Creating World-Class Oncology Organization; Launched Significant Number of New Products and Indications; and Realigned...

CAMBRIDGE, Mass., October 25, 2023 - Mediar Therapeutics Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt fibrosis progression, today announced several...

/PRNewswire/ -- About 9.4% of the world population is aged 65 or above. Older people typically consume more medicines than the people in other age group...

/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug...

By Adam L. Cataldo Cardiff Oncology's shares climbed after the company said it would advance its lead program--a possible treatment for colorectal...

 - Advance to first-line RAS-mutated mCRC follows the strong signal from new clinical and preclinical data, and agreement with FDA -  - First-line mCRC represents substantial increase in patient...

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Pfizer’s Primary Care segment, which consists of its internal medicine drugs and vaccines, makes up the bulk of its revenues

PFE earnings call for the period ending March 31, 2023.